Protocol EC-FV-03: A phase II study of EC145 in patients with progressive adenocarcinoma of the lung.
Phase of Trial: Phase II
Latest Information Update: 10 Mar 2015
At a glance
- Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Endocyte; Merck Sharp & Dohme
- 01 Mar 2013 Results have been presented at the 2013 AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy according to an Endocyte media release. Results were also summarised in the media release.
- 07 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Mar 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History